Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $92.79 Average Target Price from Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been given an average recommendation of “Moderate Buy” by the fourteen analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $92.79.

Several research analysts have weighed in on the company. Canaccord Genuity Group lifted their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Piper Sandler cut their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a research report on Monday, March 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. JPMorgan Chase & Co. raised their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. Finally, HC Wainwright reissued a “buy” rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $35.40 on Friday. The firm has a market capitalization of $3.32 billion, a price-to-earnings ratio of -5.58 and a beta of 0.61. Ultragenyx Pharmaceutical has a 52 week low of $29.59 and a 52 week high of $60.37. The business’s fifty day moving average price is $38.25 and its two-hundred day moving average price is $43.99.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The firm had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. As a group, research analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CAO Theodore Alan Huizenga sold 967 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the completion of the transaction, the chief accounting officer now directly owns 50,265 shares of the company’s stock, valued at approximately $2,116,156.50. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emil D. Kakkis sold 25,000 shares of the stock in a transaction on Friday, February 28th. The stock was sold at an average price of $42.48, for a total value of $1,062,000.00. Following the sale, the chief executive officer now owns 2,158,985 shares in the company, valued at approximately $91,713,682.80. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 124,643 shares of company stock valued at $5,256,268. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. raised its position in shares of Ultragenyx Pharmaceutical by 740.0% in the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock worth $4,802,000 after buying an additional 76,150 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Ultragenyx Pharmaceutical by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock valued at $928,000 after acquiring an additional 294 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Ultragenyx Pharmaceutical by 4.4% in the third quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company’s stock worth $87,296,000 after purchasing an additional 65,623 shares during the last quarter. KBC Group NV increased its holdings in shares of Ultragenyx Pharmaceutical by 2,275.8% in the 4th quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company’s stock worth $2,567,000 after buying an additional 58,442 shares during the last quarter. Finally, Nordea Investment Management AB raised its holdings in shares of Ultragenyx Pharmaceutical by 8.9% during the 4th quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company’s stock valued at $1,658,000 after buying an additional 3,246 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.